• In October 2023, Alfasigma S.p.A. announced its agreement to acquire the Jyseleca business from Galapagos, a Belgian multinational biotechnology company focused on developing innovative treatments for immunology and oncology.

• In July 2023, Boehringer Ingelheim International GmbH received approval from the U.S. FDA for Cyltezo (adalimumab-adbm), an interchangeable biosimilar to HUMIRA, to treat a range of chronic inflammatory diseases, including rheumatoid arthritis (RA), in the U.S.

In this report, the Rheumatoid Arthritis Therapeutics Market has been segmented by Molecule Type, Product Type, Sales Channel, Distribution Channel, and Geography.

Rheumatoid Arthritis Therapeutics Market, Segmentation by Molecule Type

The Rheumatoid Arthritis Therapeutics Market has been segmented by Molecule Type into Pharmaceuticals, and Bio-pharmaceuticals.

Pharmaceuticals

Pharmaceuticals account for approximately 43.27% of the market. This segment includes nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease-modifying antirheumatic drugs (DMARDs) such as methotrexate and sulfasalazine. These molecules are widely used for their cost-effectiveness, rapid symptom relief, and established presence in first-line therapy protocols.

Bio-pharmaceuticals

Bio-pharmaceuticals dominate the market with a share of around 56.73%. This category includes biologics such as TNF inhibitors, interleukin blockers, and JAK inhibitors that target specific immune pathways to control inflammation and slow disease progression. Their increasing adoption is driven by superior clinical outcomes, personalized treatment strategies, and growing availability of biosimilars.

Rheumatoid Arthritis Therapeutics Market, Segmentation by Product Type

The Rheumatoid Arthritis Therapeutics Market has been segmented by Product Type into Biologics, Non-Biologics, NSAIDs, SDMARDs, and Others.

Biologics

Biologics dominate the market with a share of approximately 38.64%. These include monoclonal antibodies, TNF inhibitors, and interleukin blockers that offer targeted immune modulation to reduce inflammation and prevent joint damage. Biologics are preferred for moderate to severe RA cases and are often used when conventional therapies fail to show adequate response.

Non-Biologics

Non-biologics account for about 21.56% of the market. This group includes conventional synthetic DMARDs (csDMARDs) such as methotrexate, leflunomide, and sulfasalazine, which remain the first-line therapy in most treatment protocols. They are widely accessible, cost-effective, and effective in managing early-stage rheumatoid arthritis.

NSAIDs

NSAIDs hold a share of approximately 17.82%. These medications, including ibuprofen, naproxen, and diclofenac, are used for symptom relief by reducing pain and inflammation. While they do not alter disease progression, they are commonly prescribed as adjunctive therapy for rapid control of acute flare-ups.

SDMARDs

SDMARDs (slow-acting DMARDs) comprise about 13.47% of the market. These agents provide long-term disease control, especially in chronic RA management. Though slower in onset, they are essential for maintaining remission and are often used in combination regimens with biologics or NSAIDs.

Others

The "Others" category holds roughly 8.51% of the market. It includes JAK inhibitors, natural remedies, and experimental drugs under development or limited use. Growing interest in novel small molecules and alternative therapies is gradually expanding this segment's presence.

Rheumatoid Arthritis Therapeutics Market, Segmentation by Sales Channel

The Rheumatoid Arthritis Therapeutics Market has been segmented by Sales Channel into Prescription, and Over-the-Counter (OTC).

Prescription

Prescription-based sales dominate the market with a share of approximately 86.24%. Most rheumatoid arthritis treatments, including biologics, DMARDs, and JAK inhibitors, require medical supervision due to their complex dosing, potential side effects, and need for ongoing monitoring. Physicians play a central role in treatment customization, making this channel the primary mode of distribution.

Over-the-Counter (OTC)

The OTC segment accounts for about 13.76% of the market. It includes easily accessible NSAIDs, topical pain relievers, and supplements used for mild symptom relief and supportive care. Although limited in scope, the OTC segment is growing due to increased self-medication trends, early-stage symptom management, and the rising popularity of natural and alternative remedies.

Rheumatoid Arthritis Therapeutics Market, Segmentation by Distribution Channel

The Rheumatoid Arthritis Therapeutics Market has been segmented by Distribution Channel into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy.

Hospital Pharmacy

Hospital pharmacies lead the market with a share of approximately 48.36%. These channels are the primary source for biologics, injectable therapies, and other high-cost treatments that require inpatient care, medical supervision, or special handling. Their dominance is supported by the availability of specialist consultations, emergency support, and adherence to hospital-based treatment protocols.

Retail Pharmacy

Retail pharmacies hold around 34.91% of the market. They offer convenient access to prescription medications such as NSAIDs, DMARDs, and oral therapies. Retail outlets serve a broad base of outpatients, providing ease of refill, counseling, and increasing availability of branded and generic medications across urban and suburban areas.

Online Pharmacy

Online pharmacies represent about 16.73% of the market. This segment is expanding rapidly due to the convenience of home delivery, growing use of telemedicine, and increased access to chronic care medications. It plays a key role in providing cost-effective options, supporting subscription-based therapy plans, and improving adherence rates for long-term rheumatoid arthritis management.

Rheumatoid Arthritis Therapeutics Market, Segmentation by Geography

In this report, the Rheumatoid Arthritis Therapeutics Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Rheumatoid Arthritis Therapeutics Market Share (%)

North America

North America holds the largest market share at approximately 39.72%. The region benefits from strong healthcare infrastructure, widespread use of biologics, and rapid adoption of advanced immunotherapies. The United States leads due to a high prevalence of rheumatoid arthritis, robust insurance coverage, and ongoing clinical research into novel RA treatments.

Europe

Europe accounts for around 27.83% of the market. Growth is supported by increasing use of biosimilars, government-funded healthcare programs, and rising awareness of early diagnosis and treatment. Countries like Germany, France, and the United Kingdom are key contributors, driven by structured rheumatology care systems and access to innovative therapies.

Asia Pacific

Asia Pacific holds about 20.64% of the market and is growing steadily due to rising cases of RA, improving healthcare accessibility, and expansion of local pharmaceutical manufacturing. China, India, and Japan are major markets, with increasing demand for affordable biologics, generic DMARDs, and government healthcare initiatives.

Middle East and Africa

This region contributes roughly 6.19% of the market. Growth is driven by improving healthcare infrastructure, rising awareness of autoimmune diseases, and increased availability of RA medications in urban centers. Countries such as Saudi Arabia, South Africa, and the United Arab Emirates are gradually adopting more specialized RA treatments.

Latin America

Latin America represents about 5.62% of the market. Increasing access to public healthcare, expansion of rheumatology clinics, and demand for cost-effective therapies are fueling growth. Brazil, Mexico, and Argentina are the leading markets, supported by initiatives aimed at early RA screening and management.

This report provides an in depth analysis of various factors that impact the dynamics of Global Rheumatoid Arthritis Therapeutics Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers:

• Significant advances in biotechnology field
• Rising prevalence of rheumatoid arthritis

• Increase in healthcare expenditure levels - The steady increase in healthcare expenditure levels across developed and emerging economies is a major driver for the global rheumatoid arthritis therapeutics market. Higher spending allows governments and private sectors to invest in advanced treatment modalities, including biologic drugs, targeted synthetic DMARDs, and personalized care strategies. This financial growth has also enabled the expansion of healthcare infrastructure, greater access to specialist care, and improved patient monitoring systems, ultimately supporting better disease management and treatment outcomes.

  Additionally, rising expenditure facilitates broader insurance coverage and government reimbursement programs, making costly rheumatoid arthritis therapies more accessible to patients. Increased funding for research and development also accelerates the discovery of innovative therapeutics and diagnostic tools. With more resources allocated toward chronic disease management, healthcare systems are better equipped to handle the growing prevalence of rheumatoid arthritis, thereby propelling market expansion.

Restraints:

• High costs of treatment options
• Adverse side effects of biologics

• Complex and evolving regulatory challenges - Complex and evolving regulatory challenges pose a significant restraint to the global rheumatoid arthritis therapeutics market. Regulatory authorities across different regions have distinct approval processes, clinical trial requirements, and pharmacovigilance standards, which complicate global product development and commercialization. Adapting to constantly shifting frameworks, such as updates in biosimilar approvals or post-market surveillance guidelines, demands substantial time, expertise, and financial investment from pharmaceutical companies.

  Furthermore, the introduction of innovative therapies and biologics often faces rigorous scrutiny regarding safety, efficacy, and long-term effects, delaying their market entry. Manufacturers must also navigate uncertainties in pricing regulations and reimbursement policies, which vary widely across countries. These challenges can hinder pipeline progression, limit product availability in certain markets, and increase operational burdens, collectively slowing the growth of rheumatoid arthritis treatment solutions.

Opportunities:

• Ongoing innovations in biopharmaceutical sector
• Expansion of personalized medicine approaches

• Emphasis on patient health education - The growing emphasis on patient health education presents a significant opportunity for the global rheumatoid arthritis therapeutics market. Empowering patients with knowledge about the disease, treatment options, and self-management strategies improves adherence to prescribed therapies and enhances long-term outcomes. Educational initiatives led by healthcare providers and patient advocacy groups are instrumental in encouraging early diagnosis, promoting regular treatment, and reducing disease progression through informed decision-making.

  Increased awareness also supports higher adoption of advanced therapeutics such as biologics and targeted DMARDs, as patients become more confident in exploring innovative options. In underserved regions, focused educational campaigns can bridge access gaps and combat misconceptions, ultimately expanding the treated patient population. As digital health platforms continue to grow, the ability to deliver tailored educational content remotely will further amplify patient engagement and drive market expansion.

Key players in Global Medical Oxygen Systems Market include:

• AbbVie, Inc.
• Boehringer Ingelheim GmbH
• Novartis International AG
• Regeneron Pharmaceuticals, Inc.
• Pfizer Inc.
• Bristol-Myers Squibb.
• F. Hoffmann-La Roche AG
• UCB S.A.
• Johnson & Johnson.
• Amgen Inc.

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Market Share Analysis
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis